Stocks and Investing
Stocks and Investing
Thu, October 13, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Michael Schmidt Upgraded (BGNE) to Strong Buy and Held Target at $205 on, Oct 13th, 2022
Michael Schmidt of Guggenheim, Upgraded "BeiGene, Ltd." (BGNE) to Strong Buy and Held Target at $205 on, Oct 13th, 2022.
Michael has made no other calls on BGNE in the last 4 months.
There is 1 other peer that has a rating on BGNE. Out of the 1 peers that are also analyzing BGNE, 0 agree with Michael's Rating of Hold.
This is the rating of the analyst that currently disagrees with Michael
- Xiling Chen of "JP Morgan" Initiated at Buy and Held Target at $296 on, Tuesday, August 9th, 2022
Contributing Sources